Parnassus Investments 13F: Adds $33M to Stryker (SYK) Stake

Parnassus Investments boosted its holdings in Stryker Corporation (NYSE:SYK) by 120,008 shares during the quarter, bringing its total stake to 2,044,522 shares. According to a Form 13F filing with the SEC on October 22, 2026, the updated investment was worth about $563 million. Stryker closed at $307.08 on the day of the filing.

SYK Stryker Corporation

$307.08 ▼ -11.05% year to date

1M 3M YTD

Daily close · Oct 22, 2026

What Changed in Parnassus Investments's Stryker Position

The fund increased its position by 6.2%, adding to its previous holding of 1,924,514 shares. This brings the total reported value of the stake to $563,040,914.

Other Institutional Activity in Stryker Corporation

Other institutional investors have adjusted their positions in the medical device maker as well. E. Ohman J:or Asset Management reduced its holdings by 31,981 shares, ending with 99,490 shares worth about $27.4 million. Quilter grew its stake by 7,250 shares to reach 101,298 shares worth about $27.9 million. ASR Vermogensbeheer N.V. increased its position by 129,793 shares to hold 131,524 shares valued at roughly $36.2 million. Meanwhile, ARS Wealth Advisors Group closed out its position by selling 775 shares, and Foster Group sold its remaining 751 shares to exit its stake entirely.

Stryker Corporation Stock Up 0.9%

Stryker shares recently traded around $307.15 as of October 23, 2026, putting the stock right around its event-day close of $307.08. The medical technology company carries a market capitalization of roughly $114.15 billion. The stock trades above its 50-day moving average of $297.28, but remains below its 200-day moving average of $325.90. Over the past year, shares have traded between a low of $267.00 and a high of $392.55.

Recent Earnings

Stryker reported trailing twelve month revenue of $25.84 billion alongside basic earnings of $9.65 per share. The company operates with a net profit margin of 14.4% and a return on equity of 16.5%. Its next quarterly earnings release is scheduled for October 29, 2026.

Dividend

Stryker distributes an annual dividend of $3.52 per share to its shareholders, providing a dividend yield of 1.18%. The company's dividend payout ratio sits at 36.1%, leaving room for reinvestment in its core medical technology operations while returning cash to investors.

Insider Buying and Selling at Stryker Corporation

Company insiders have been active in the open market over recent months. Officer Robert S. Fletcher disposed of 4,544 shares on May 28, 2026, for a total value of about $1.39 million. Officer Debra King sold 826 shares on August 18, 2026, at an average price of $336.30, totaling roughly $277,787. Director Ronda E. Stryker sold 350,000 shares on August 19, 2026, worth approximately $117.78 million. Finally, officer Dylan Bram Crotty offloaded 441 shares on August 21, 2026, at $328.60 per share for a total value of about $144,915.

Analysts Set New Price Targets

Wall Street research firms continue to monitor the healthcare stock. TD Cowen maintains a hold rating with a price target of $298.00 down from $355.00 on September 22, 2026. Stifel maintains a buy rating with a price target adjusted from $360.00 to $330.00 on September 30, 2026. Truist Securities maintains a hold rating with a target of $310.00 on October 7, 2026. Barclays initiated coverage with an overweight rating and a $375.00 price target on October 7, 2026. BTIG maintains a buy rating while lowering its target from $358.00 to $316.00 on October 12, 2026. Overall, the stock holds a consensus buy rating from 26 analysts with a mean price target of $362.62.

About Stryker Corporation

Headquartered in Portage, Michigan, Stryker Corporation is a major player in medical technology. The company develops and supplies surgical equipment, neurotechnology, and orthopaedic products to hospitals and healthcare providers across the globe, supporting clinical procedures and patient recovery.

Bottom Line

Investors are keeping a close eye on Stryker as the company approaches its upcoming earnings report on October 29, 2026. Institutional moves from funds like Parnassus show continued interest in the medical equipment provider despite recent market volatility.